Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial.

The role of immunosuppression in the management of IgA nephropathy remains highly controversial. The Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial suggested that there was no benefit with the addition of immunosuppression to intensive supportive care, in terms of renal outcome. In this edition of Kidney International, Rauen et al. report long-term outcomes from the STOP-IgAN trial. Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.

Citation

Chee Kay Cheung, Jonathan Barratt. Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial. Kidney international. 2020 Oct;98(4):836-838

Mesh Tags

Substances

PMID: 32998815

search → result